Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva Braces For A Bigger Hit As Price Competition Intensifies For Copaxone

Executive Summary

Teva has been able to hold onto a roughly 85% share of the Copaxone 40 mg market, but expects pressure from generics will intensify in the second half of the year.

You may also be interested in...



Is Quarterly Dosing For Teva's Ajovy Enough To Differentiate It From Other CGRP Inhibitors?

The US FDA approved Teva's fremanezumab dosed monthly and quarterly versus Amgen's monthly Aimovig, and will launch at the same price. However, it's packaged as a pre-filled syringe instead of an autoinjector, has a higher rate of injection site reactions and it may launch alongside Lilly's Emgality.

Enthusiasm For US Biosimilars Wanes For Some, But Not Others

Three years after the first biosimilar launched in the US, the market has failed to deliver notable return on investments. Some players like Mylan are going public with frustrations over market barriers, while others, like Amgen, say they are encouraged by steady progress. Teva, however, is limiting its investment in biosimilars.

Enthusiasm For US Biosimilars Wanes For Some, But Not Others

Three years after the first biosimilar launched in the US, the market has failed to deliver notable return on investments. Some players like Mylan are going public with frustrations over market barriers, while others, like Amgen, say they are encouraged by steady progress. Teva, however, is limiting its investment in biosimilars.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL033172

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel